Twenty-five institutions collaborate with Cofactor to validate OncoPrism for use in head and neck cancer patients.
In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in [...]
Jarret Glasscock, PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time. Precision [...]
Readout from the national PREDAPT multicenter clinical trial presented at AGBT Precision Health Conference Cofactor Genomics, a Predictive Immune Modeling company, today presented initial results [...]
Comprehensive immune profiling may lead to better prediction of immunotherapy response What must we do to improve outcomes for cancer patients? The answer is simple – gain a better understanding [...]
A familiar refrain for those who have traveled on London’s tube, “mind the gap” is a warning to take caution while crossing between the station platform and the train door. In oncology, patients [...]
The race to cure cancer has focused on drug discovery; in the last five years, clinical trials increased 500% for new drugs. Genome targeted therapies were an early source of excitement, but only [...]
SAN FRANCISCO – February 15, 2022 – Cofactor Genomics today announced publication in the latest issue of Nature Scientific Reports of a study showing that the company’s multianalyte [...]
Sign up to receive the latest from Cofactor right in your inbox.
Start typing and press Enter to search
